glp 1 health concerns GLP-1 Agonists In Obesity The GLP-1 revolution: What UAB

Genetically-predicted GLP1R expression (the target of GLP-1 RAs) showed an inverse association with background [odds ratio (OR)=0.83, 95% CI, 0.710.97] and severe nonproliferative DR (OR=0.72, 95% CI, 0.530.98), and a non-significant association with overall (OR=0.97, 95% CI, 0.921.03) and proliferative DR (OR=0.98, 95% CI, 0.911.05)

Adult people (18 years) with a diagnosis of obesity (body mass index30 kg/m2) or T2DM (ICD-10-CM: E11) between 2018 and 2024 were subdivided in two mutually exclusive cohorts: (1) GLP-1 RA Users

Family physicians play a critical role in guiding patients through the complexities of injectable weight loss medication use and discontinuation.

Understanding your baseline lipid profile, genetic predispositions, and metabolic biomarkers helps guide informed conversations with healthcare providers about realistic outcomes and personalized treatment goals

A dual GIP/GLP-1 agonist studied in metabolic research